Expansion, in vivo-ex vivo cycling, and genetic manipulation of primary human hepatocytes.
Eleftherios MichailidisKoen VercauterenLiliana Mancio-SilvaLinda AndrusCyprien JahanInna Ricardo-LaxChenhui ZouMohammad KabbaniPaul ParkCorrine QuirkChristina PyrgakiBrandon RazookyLieven VerhoyeIrene ZoluthkinWei-Yu LuStuart J ForbesLuis ChiribogaNeil D TheiseRoland W HerzogHiroshi SuemizuWilliam M SchneiderAmir ShlomaiPhilip MeulemanSangeeta N BhatiaCharles M RiceYpe P de JongPublished in: Proceedings of the National Academy of Sciences of the United States of America (2020)
Primary human hepatocytes (PHHs) are an essential tool for modeling drug metabolism and liver disease. However, variable plating efficiencies, short lifespan in culture, and resistance to genetic manipulation have limited their use. Here, we show that the pyrrolizidine alkaloid retrorsine improves PHH repopulation of chimeric mice on average 10-fold and rescues the ability of even poorly plateable donor hepatocytes to provide cells for subsequent ex vivo cultures. These mouse-passaged (mp) PHH cultures overcome the marked donor-to-donor variability of cryopreserved PHH and remain functional for months as demonstrated by metabolic assays and infection with hepatitis B virus and Plasmodium falciparum mpPHH can be efficiently genetically modified in culture, mobilized, and then recultured as spheroids or retransplanted to create highly humanized mice that carry a genetically altered hepatocyte graft. Together, these advances provide flexible tools for the study of human liver disease and evaluation of hepatocyte-targeted gene therapy approaches.
Keyphrases
- hepatitis b virus
- endothelial cells
- liver injury
- gene therapy
- induced pluripotent stem cells
- plasmodium falciparum
- pluripotent stem cells
- induced apoptosis
- genome wide
- type diabetes
- copy number
- signaling pathway
- emergency department
- liver failure
- cancer therapy
- high intensity
- cell proliferation
- endoplasmic reticulum stress